CME Presentations

Pediatric Neuroblastoma - ANR



  • Jaume Mora, MD, PhD

    Jaume Mora, MD, PhD

    Jaume Mora, MD, PhD

    Scientific Director

    Jaume Mora, MD, PhD, is the scientific director of the Pediatric Cancer Center Barcelona (PCCB) at Hospital Sant Joan de Deu in Spain. He is an acclaimed international pediatric oncologist with more than 150 peer-reviewed publications in the field of developmental oncology. Dr Mora’s research specializes in the origin of childhood solid tumors with contributions in neuroblastoma, Ewing sarcoma, retinoblastoma, and DIPG. He has been distinguished with the first Research Award of Translational Oncology of the FERO Society in 2009 and the First Martí Via Award of Translational Oncology of the Fundació Vallformosa in 2015. Dr Mora specialized in pediatric hematology and oncology through the fellowship program at Memorial Sloan-Kettering Cancer Center and Cornell Medical School in New York.
  • Daniel Morgenstern, MB BChir, PhD

    Daniel Morgenstern, MB BChir, PhD

    Daniel Morgenstern, MB BChir, PhD

    Staff Oncologist

    Daniel Morgenstern, MB BChir, PhD, is a staff oncologist at Hospital for Sick Children, Toronto, and assistant professor at the University of Toronto in Canada. His clinical activities are focused on neuroblastoma and solid tumor patients participating in early-phase clinical trials. Dr Morgenstern’s research interests are in early-phase trials and the use of immune checkpoint inhibitors in pediatric cancers and the development of precision medicine approaches for pediatric solid tumors. He originally trained and worked in the UK, primarily at Great Ormond Street Hospital in London, where he was clinical lead for the neuroblastoma and autograft programs and an active member of SIOPEN.

CME Information

Effective Administration and Management of Anti-GD2 Monoclonal Antibodies for Pediatric Neuroblastoma

Global Logo PQH Logo


After completing this activity, the participant should be better able to:
  • Review the historical evolution of anti-GD2 therapy and the rationale for novel therapies
  • Differentiate administration protocols for currently available anti-GD2 therapies
  • Assess the demands on the inpatient vs the outpatient treatment teams
  • Evaluate supportive-care strategies to manage the challenges of administration and treatment-related adverse effects of anti-GD2 therapy for pediatric neuroblastoma
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.


This activity is supported by an educational grant from Y-mAbs Therapeutics, Inc.


Monday, January 25, 2021 from 2:00pm – 3:00pm ET


The educational design of this activity addresses the needs of pediatric oncology nurses, advanced practice providers (including nurse practitioners and physician assistants), pediatric oncologists, social workers, and other members of the team caring for children with pediatric neuroblastoma.


Next-generation anti-GD2 therapies have expanded the treatment landscape for relapsed/refractory high-risk pediatric neuroblastoma. With few treatment options in this setting, anti-GD2 agents hold the promise of reducing the burden of care on patients and their families, including time spent in the hospital and financial, professional, and personal concerns.

To help achieve these goals, this activity will provide clinicians with critical updates on the scientific evidence related to these therapies. A multidisciplinary panel of experts in pediatric neuroblastoma and anti-GD2 therapy will review the nuances of treatment administration and delivery, along with the management of adverse events. Return to your practice with supportive-care protocols designed to facilitate safe and effective care for your patients with pediatric neuroblastoma, and to improve quality of life for these patients and their families.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

* This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.


Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Jaume Mora, MD, PhD
Scientific Director
Pediatric Cancer Center Barcelona
Hospital Sant Joan de Deu
Advisory Board: Y-mAbs Therapeutics
Daniel Morganstern, MD BChir, PhD
Staff Oncologist
Hospital for Sick Children, Toronto
Consultant/Independent Contractor: Bayer, Clarity Pharmaceuticals, EUSA Pharma, Y-mAbs Therapeutics
Grant/Research Support: Bristol Myers Squibb
Speaker's Bureau: Y-mAbs Therapeutics
Advisory Board: Boehringer-Ingelheim, Roche
Jennifer Cabral H.BSc, RN
Clinical Program & Research Nurse Coordinator
New Agents and Innovative Therapies
Solid Tumour Team
Oncology Program
Hospital for Sick Children, Toronto
Consultant/Independent Contractor: Y-mAbs Therapeutics

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Ashley Marostica, RN, MSN Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Jaimee Harris-Gold Nothing to disclose
Tariqa Ackbarali Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at